Alliance Pharma (APH)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

35.40p
   
  • Change Today:
      0.25p
  • 52 Week High: 70.00p
  • 52 Week Low: 29.35p
  • Currency: UK Pounds
  • Shares Issued: 540.40m
  • Volume: 1,314,613
  • Market Cap: £191.30m
  • RiskGrade: 119

Wednesday broker round-up UPDATE

Date: Wednesday 24 Sep 2014

LONDON (ShareCast) - Aggreko: Morgan Stanley ups target price from 1350p to 1375p, while leaving its underweight rating unaltered.
Alliance Pharma: Canaccord Genuity lowers target price from 35p to 33p reiterating its hold recommendation.

Close Brothers Group: UBS moves target price from 1420p to 1430p and keeps a neutral rating. JP Morgan ups target price from 1512p to 1580p and stays with an overweight rating.

Cobham: Citi ups target price from 290p to 305p and reiterates a neutral rating.

Darty: JP Morgan cuts target price from 85p to 65p and leaves its underweight rating unchanged.

Greenko Group: Investec ups target price from 275p to 310p and maintains a buy recommendation.

Johnston Press: Citi shifts target price from 1p to 4p upgrading to neutral.

Nostra Terra Oil & Gas: Northland Capital places its target price (prev.: 0.56p) under review with a buy recommendation.

Outsourcery: Investec reduces target price from 130p to 71p, while its buy recommendation remains unchanged.

Partnership Assurance: Nomura lowers target price from 145p to 134p and keeps a neutral rating.

Standard Chartered: Berenberg reduces target price from 1200p to 1100p, while staying with its hold recommendation.

Rightmove: Citi reduces target price from 3650p to 2175p downgrading to sell.

Rio Tinto: Morgan Stanley raises target price from 3540p to 4000p upgrading from equal-weight to overweight.

Royal Bank of Scotland: Numis lowers target price from 378p to 368p and maintains a hold recommendation.

Standard Life: Nomura ups target price from 390p to 410p and maintains its neutral rating.

Tate & Lyle: Credit Suisse cuts target price from 630p to 600p and retains an underperform rating. Citi reduces target price from 800p to 685p keeping a buy recommendation. Societe Generale cuts target price from 745p to 640p downgrading to hold. UBS upgrades from sell to neutral with a target price of 615p. Canaccord Genuity reduces target price from 640p to 530p downgrading to sell. Numis cuts target price from 698p to 572p and retains a hold recommendation. Berenberg reduces target price from 775p to 665p downgrading from buy to hold.

Tesco: Citi reduces target price from 300p to 190p and keeps a neutral rating.

Trinity Mirror: Citi raises target price from 50p to 204p upgrading to neutral.

Zoopla Property: Citi initiates with a target price of 245p and a neutral rating.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alliance Pharma Market Data

Currency UK Pounds
Share Price 35.40p
Change Today 0.25p
% Change 0.71 %
52 Week High 70.00p
52 Week Low 29.35p
Volume 1,314,613
Shares Issued 540.40m
Market Cap £191.30m
RiskGrade 119

Alliance Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.33% above the market average92.33% above the market average92.33% above the market average92.33% above the market average92.33% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
68.62% below the market average68.62% below the market average68.62% below the market average68.62% below the market average68.62% below the market average
14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average
Income
32.16% above the market average32.16% above the market average32.16% above the market average32.16% above the market average32.16% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
89.29% below the market average89.29% below the market average89.29% below the market average89.29% below the market average89.29% below the market average
88.24% below the sector average88.24% below the sector average88.24% below the sector average88.24% below the sector average88.24% below the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 3
Sell 0
Strong Sell 0
Total 7
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Alliance Pharma Dividends

  Latest Previous
  Final Interim
Ex-Div 22-Jun-23 22-Dec-22
Paid 18-Jul-23 19-Jan-23
Amount 1.18p 0.59p

Trades for 17-May-2024

Time Volume / Share Price
16:35 68,902 @ 35.40p
16:35 618 @ 35.40p
16:35 491 @ 35.40p
16:35 2,455 @ 35.40p
16:35 2,462 @ 35.40p

Alliance Pharma Key Personnel

CEO Peter Butterfield
CFO Andrew Franklin
Chair Camillo Pane

Top of Page